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Summary. In the article all the basic characteristics, clinical significance, risk factors, pathogenesis, prevention and
treatment modalities of ovarian hyperstimulation syndrome were described. In the introduction all the main characteristics,
classifications and incidence of the syndrome were noted. The best known risk and predictive factors that characterize the
patients at risk with their significance include polycystic ovarian disease, multiple and immature follicles, young age (<35
years), lean habitus, high serum estradiol (>3000 pg/ml), hypothyroidism, hyperprolactinemia, oligomenorrhea, anovula-
tory infertility, stimulation protocols with gonadotrophin releasing hormone agonists, and human chorionic gonadotrophin
for the induction of ovulation and luteal support were reported. To understand modern etiologic aspects and pathophysio-
logic mechanisms in the development of the syndrome the underlying causes of all relevant vasoactive substances were
described. In the prophylaxis of the syndrome all significant and judicious methods and procedures which could prevent
the appearance of symptoms were reported. Modern strategies for the treatment of OHSS which include macromolecular
plasma expanders with its usefulness and controversies, diuretics, paracentesis, anticoagulants and surgery, that could
reduce the complications and long-term sequels were described.
Pregled
Klju~ne rije~i: sindrom hiperstimulacije jajnika, jajnici, stimulacija
Sa‘etak. U ~lanku su opisane temeljne karakteristike, rizi~ni faktori, patogeneza, prevencija i lije~enje sindroma hiper-
stimulacije jajnika. U uvodu ~lanka istaknut je patolo{ki supstrat, klini~ki zna~aj bolesti i komplikacije koje mogu vitalno
ugroziti zdravlje bolesnica. U~estalost i klini~ka slika sindroma hiperstimulacije klasificirana je prema te‘ini i brojnosti
postoje}ih simptoma, lokalnom nalazu, poreme}ajima u krvnoj slici, pojavi ascitesa i op}em stanju, na tri stupnja bolesti:
blagi, srednji i te{ki. U poglavlju o rizi~nim faktorima istaknute su skupine bolesnica koje treba uo~iti prije profilakse i
lije~enja bolesti, od kojih su najva‘niji sindrom policisti~nih jajnika, multipli i nezreli folikuli, mla|a ‘ivotna dob (<35
godina), asteni~ni habitus, povi{ena razina estradiola u krvi (>3000 pg/ml), hipotireoza, hiperprolaktinemija, oligomenoreja,
anovulacijska neplodnost, stimulacijski protokoli s agonistima gonadotropnih osloba|aju}ih hormona te egzogeni ili endo-
geni (rana trudno}a) humani korionski gonadotropin. U poglavlju o patofiziologiji koja jo{ nije potpuno razja{njena,
navedeni su, prema najnovijim spoznajama, zna~aj citokina i mehanizmi njihova djelovanja u nastanku bolesti. Istaknuta
je klju~na uloga prevencije u olak{avanju ili spre~avanju sindroma hiperstimulacije primjenom raznih metoda, od kojih se
navode prestanak ili prolazno odustajanje od stimulacije u tom ciklusu, smanjivanje doze humanog korionskog gonadotro-
pina te primjena rekombinantnog luteiniziraju}eg hormona ili agonista gonadotropnog osloba|aju}eg hormona za induk-
ciju ovulacije, antidota ili inhibitora citokina, kortikosteroida, metformina te aspiracije folikula. U lije~enju bolesti potvr|ena
je vrijednost plazma ekspandera albumina, premda su kasnija istra‘ivanja relativizirala njegovu djelotvornost, u~iniv{i ju
prijepornom, upitnom ili ~ak {tetnom. U terapijskom pristupu nadalje su istaknuti va‘nost, opravdanost te indikacije za
primjenu diuretika, antikoagulancija, paracentezu i kirur{kog lije~enja.
Introduction
Ovarian hyperstimulation syndrome (OHSS) is the most
serious complication of ovulation induction. This iatro-
genic condition severely impacts the patient’s health,
leading to morbidity and even mortality. The syndrome
is characterized by ovarian enlargement and vascular hy-
perpermeability which accompanies fluid shifts from in-
travascular to extravascular space, including formation
of ascites, hypotension, hemoconcentration, electrolyte
disturbances, abdominal distension and discomfort, liver
and kidney dysfunctions, hydrothorax, and even throm-
boembolic phenomena.1–4
The oldest OHSS classification scheme consisted of
six levels (Rabau 1967),5 which was later modified (Schen-
ker 1978)6 into three categories: mild, moderate, and se-
vere, each with two grades of severity, A and B. The
newest and widely accepted classification scheme em-
phasises clinical signs of the syndrome (Golan 1989),7
which is also divided into three categories: mild, moder-
ate, and severe. Mild grade of the syndrome is charac-
terized with high estradiol (E2) serum levels, mild ab-
dominal distension, large ovaries up to 12 cm in diameter,
nausea, vomiting, and diarrhea. Moderate level of OHSS
include mild signs with clinical evidence of ascites and
hydrothorax. Severe OHSS is further aggravated by he-
moconcentration, coagulation and electrolyte disorders,
oliguria/anuria, renal failure, hypovolemic shock, and ovar-
ian enlargement above 12 cm.1,3,7 Classically, the inci-
dence of OHSS has been reported to vary from 8–23%
in mild, 0.5–7%, in moderate, 0.8–10% in its severe form,
respectively.3
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Risk factors
Patients at risk of developing OHSS should be identi-
fied prior to preventive medicine and treatment because
of risk factors or clinical predictors. The best known risk
factor for OHSS is polycystic ovarian disease (PCOD),
and a luteinizing hormone (LH) and follicle stimulating
hormone (FSH) ratio higher than two is a valuable pre-
dictive tool. A novel ultrasonic risk factor, »the neck-
lace« sign of the ovaries, is characterized by the presen-
ce of multiple small, immature, and intermediate, early,
antral follicles 2 to 8 mm in diameter that are arranged
as a string or palisade around the periphery of the ovary
with abundant stroma in the deeper ovarian structures.
This was described by several authors during the early
follicular phase and eventually linked to OHSS. Although
frequent in patients with a PCOD-like picture, this sign
may appear in an individual with normal 25 to 35 day
cycles.1,8,9
Similarly, OHSS correlates positively with luteal sup-
plementation with human chorionic gonadotrophin (HCG)
and conceptual cycles and is almost exclusively related
to either exogenous or endogenous HCG stimulation.5,6
Other risk factors that are widely accepted include young
age (<35 years), lean (asthenic) habitus, high serum E2
levels, hypothyroidism, hyperprolactinemia, oligomen-
orrheic and anovulatory infertility.1,10 However, others
have failed to find a correlation between either body mass
index or body weight with propensity for OHSS.11
Peak levels of E2 are significantly higher in in vitro
fertilization (IVF) cycles complicated by OHSS than in
the control cycles. It has been suggested that the rate of
serum E2 rise is more important than the absolute levels,
with very rapid rises reflecting hypersensitivity of the
ovary to stimulation. It was anticipated that it would be
possible to define a peak limit of serum E2, above which
the risk of OHSS would be so high that the treatment
cycle should be abandoned, thereby avoiding OHSS. Al-
though a marked interinstitutional variability of E2 lev-
els exist and there is a lack of agreement as to the upper
limit of E2, many authors consider that a significant risk
of developing OHSS is increased once the concentration
of 3000 pg/mL is reached, with different investigators
quoting values from 1500 pg/mL to greater than 6000 pg/
mL.12,13 Asch et al.14 described a 38% risk of severe OHSS
in IVF cycles with peak E2 concentration exceeding 6000
pg/mL on the day of HCG administration and reported a
good correlation between the number of follicles on ul-
trasound scan and the number of oocytes retrieved, and
observed a 23% risk of severe OHSS if more than 30
oocytes were obtained. Morris et al.17 found that the same
criterion, using the same E2 assay, predicted only 8.8%
risk of severe OHSS. The levels of E2 alone do not pro-
vide a clinically useful guide to the risk of OHSS, both
because of the considerable overlap with normal cycles
and the variation in assay results between laboratories.
If no single factor can predict OHSS it might be hoped
that a combination of features would be more success-
ful.1,12–17
In addition to the epidemiologic, hormonal, and ultra-
sonic criteria, various stimulation protocols may offer
relative protection of increased risk. OHSS may develop
after ovulation induction with exogenous gonadotrophins
or Clomiphene citrate (CC) followed by HCG which is
required for triggering of ovulation. Luteinization, there-
fore, appears to be a prerequisite for the development of
OHSS.18 The sensitivity of the ovary to gonadotrophic
stimulation and the magnitude of the ovarian response
to gonadotrophins appear to be important determinants
of the probability of developing OHSS, especially of »ear-
ly« clinical form which appear 3–7 days after the ovula-
tory dose of HCG, whereas, »late« form of OHSS is more
likely to be severe and appears 12–17 days following
HCG and depends on the occurrence of pregnancy.12,14,18
Women who develop OHSS, especially with low body
mass index and PCOD, require significantly lower doses
of human menopausal gonadotrophins (HMG) for stim-
ulation and have a lower ratio of HMG dose duration of
stimulation than the matched controls. There is no evi-
dence that the use of purified FSH for ovarian stimula-
tion alters the risk of OHSS. Studies comparing HMG
and FSH for controlled ovarian stimulation do not indi-
cate that one is better than the other with regard to the
risk of OHSS. Several investigators have described the
use of purified FSH in low doses by a step-up or incremen-
tal regimen in previously hyper-responsive patients1,12,20,21
The routine use of gonadotrophin releasing hormone ag-
onists (GnRH-a) for controlled ovarian stimulation has
introduced an additional, though paradoxical, risk factor.
A number of mechanisms have been described to account
for this including the initial »flare-up,« a direct effect of
GnRH-a on the ovarian stroma, and inhibition of prema-
ture luteinisation. GnRH agonists, by allowing us to pro-
long the stimulatory phase, abolish the body’s protec-
tive mechanism of early luteinization, resulting in high-
er E2 values and a larger number of follicles selected.
Thus, in contrast to patients with hypogonadotrophic hypo-
gonadism, »medical hypophysectomy« induced GnRh-a
confers increased risk rather than protection. Thus, the
use of GnRH-a may be blocking a self-protecting mech-
anism (spontaneous LH surge with luteinization) that will
check any further stimulation. In addition, the use of pi-
tuitary down-regulation requires that ovulation be in-
duced by HCG, with probably higher risks of OHSS than
the use of endogenous LH for ovulation.21,22
Pathogenesis
Because the intensity of the OHSS is related to the
degree of ovarian response to ovulation induction thera-
py, OHSS is probably an exaggeration of normal ovarian
physiology.3 In understanding pathophysiology of OHSS
it is essential to the rational development of strategies
for preventing and treating it. The underlying cause of
OHSS is not clearly known, but a vasoactive ovarian fac-
tor is likely to be involved. It is now generally accepted
that this factor is liberated by the corpora lutea into the
bloodstream where it is dispersed and exerts its effects.
A vasoactive substance secreted by the ovaries under HCG
64
Gynaecol Perinatol 2004;13(2):62–68 Kasum M. Ovarian hyperstimulation syndrome
stimulation plays a key role in triggering the syndrome.
Several substances have been proposed as the interme-
diary responsible for the increase in capillary permea-
bility. Physiologically, this increase in capillary permea-
bility results from a contraction of endothelial cells which
leads to gap formation in between adjacent cells that al-
lows a form of capillary transport and leads to third spac-
ing. A number of studies have suggested several vasoac-
tive substances and various pathophysiologic mechanisms,
but a distinction should however be made between pri-
mary processes and compensatory mechanisms that are
secondarily activated in the course of OHSS. The candi-
date mediators are cytokines (including allergenes-cyto-
kines-histamine as a system), vascular endothelial growth
factor (VEGF), angiogenin, the kinin kallikrein system,
selectins, von Willebrand factors, prolactin, prostaglan-
dins and the ovarian prorenin-renin-angiotensin system.
The main conclusion is that OHSS is the result of distur-
bance of the basic inflammation – like normal ovulation
process, and has its main feature of capillary leakage
and transmission to other compartments.24–26
Because several cytokines, IL-2, IL-8, and especially
IL-6, tumor necrosing factor alpha (TNF-alpha) mediate
increases in vascular permeability and suppression of he-
patic albumin production, that indicate its potential util-
ity as OHSS markers. It was noticed that the serum con-
centrations of cytokines declined in parallel with the im-
provement of clinical conditions and resolution of OHSS
which may be useful in the evaluation of severity of the
syndrome. Because follicular fluid IL-6 concentrations
at the time of oocyte retrieval and serum IL-8 concentra-
tions at the time of embryo transfer were significantly
higher in OHSS, that may serve as early predictors for
this syndrome.27,28
In addition to inducing angiogenesis of endothelial cells
in dominant follicle and corpus luteum of a natural cycle,
which is more pronounced during ovarian stimulation,
VEGF is regarded as the major capillary permeability fac-
tor in OHSS ascites, because 70% of the capillary per-
meability activity was neutralized by recombinant VEGF
antiserum.3,29,30 It was found that IVF patients suffering
from OHSS had follicular, plasma and ascitic VEGF lev-
els which were significantly higher and correlated to the
clinical picture. Although HCG which binds to microv-
ascular endothelial cells as a primary target plays a key
role in the up-regulation and acute release of VEGF in
OHSS, the addition of potent synthetic progesterone an-
tagonist RU-486 reduces the extension of OHSS, which
demonstrates that progesterone is in part implicated in
the development of the sydrome.31–33 It was noticed that
the increased levels of VEGF under the action of gona-
dotrophins, act through an overexpressed VEGF recep-
tor-2, that may be responsible for the accumulation of
ascitic fluid.34,35 Because VEGF levels are elevated in all
the patients with hyperstimulated ovaries there is no sig-
nicant difference between those who develop OHSS and
those who do not, and therefore plasma VEGF levels are
poorly predictive of subsequent OHSS.36 Because the pa-
tients with developed OHSS had significantly more free
or unbound VEGF and lower follicular fluid and plasma
levels of the binding protein, that offers a hypothesis of
intermediate relationship which determines the patient
who will be prone to OHSS.37,38
Many investigators have highlighted the role of the
ovarian renin-angiotensin system and other endogenous
vasoconstrictor systems in the evolution of systemic ma-
nifestations OHSS leading to the consideration of angi-
otensin converting enzyme (ACE) inhibitor to prevent
or modify the course of OHSS.39,40 However, it was shown
that the primary importance in the pathogenesis of OHSS
belongs to peripheral arterial vasodilatation suggesting
that the activation of the renin-angiotensin system seen
in OHSS might represent a secondary homeostatic re-
sponse, rather than a primary pathogenic mechanism of
the syndrome. Inhibition of angiotensin synthesis may
not, therefore, be the key to preventing the actual occur-
rence of the syndrome, but may modify its course once
established.41,42
Prevention
Key to the prevention of OHSS is a proper identifica-
tion of the population at risk. Various methods for proph-
ylaxis of OHSS or diminishing its severity have been
suggested. Approximately two-thirds of the physicians
preferred to apply some preventive measures while oth-
ers selected only one preventive method.1,3,16,25,26
The oldest and the most effective has been to abandon
the cycle. However, only 11% physicians would consider
cancelling it because of high costs and tremendous hopes
fostered by the couple. No relationship was found be-
tween the case-scenario description and the decision to
cancel the cycle, although there was a relationship with
the peak E2 concentration chart. However, even in the
most severe case, for which a peak E2 level of 6590 pg/mL
was rapidly reached, only a fifth of the physicians would
consider cancelling that cycle. Furthermore, some phy-
sicians commented spontaneously that in their country
only a limited number of IVF treatments are reinbursed
by social security or insurance plans, whether the trials
are completed or not. One may feel that it is neither ethi-
cally acceptable to have these factors influence the deci-
sion to proceed to a potentially dangerous procedure.26
Among different preventive measures, coasting clearly
represents the most popular choice which is a preferred
technique for about 60% physicians. The advantage of
this technique is that the cycle is not abandoned i.e. in-
duction of ovulation is stopped and HCG is witheld until
serum E2 level decreases to »a safer zone«. In addition,
coasting can be carried out in all countries, which is not
the case for cryopreservation and the use of recombinant
LH (r-LH). Some of the main retrospective studies pre-
sented encouraging results after coasting i.e. that the
chances of pregnancy remain unaffected. However, others
regarded coasting as effective as i.v. albumin in prevent-
ing OHSS in high risk patients but with inferior preg-
nancy rates. In addition, the longer the interval between
discontinuing gonadotrophin administration and the ad-
ministration of HCG, the lower the conception rate is
likely to be.12,13,43,44
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The ovulatory doses of HCG vary between centres from
1000 IU to 25 000 IU. The customary, average dose of
ovulatory HCG is 10000 IU. Higher doses of HCG (10000
IU or more) are associated with a higher incidence of
OHSS, but using a reduced dose of HCG (5000 IU) would
exert a shorter period of stimulation and alleviate the
symptoms of the syndrome. However, doses of HCG less
than 5000 IU are associated with lower conception rates.
The optimum dose of HCG is, therefore, a compromise
between efficacy and comparative safety. Native LH dif-
fers significantly from HCG in significantly shorter half-
life and binding to ovarian receptors with lower affinity
and for a shorter duration than HCG. These characteris-
tics would sugest that an endogenous LH surge produces
less sustained luteotrophic stimulation and is less relia-
ble to be followed by OHSS than exogenously adminis-
tered HCG.16,25,45,46
Theoretically, a variety of hormonal and pharmaco-
logical compounds can be used as substitutes for the mid-
cycle LH surge. Because the use of GnRh-a to effect
pituitary down-regulation prior to initiation ovarian stim-
ulation is associated with an increased risk of developing
OHSS, the administration of r-LH derived from geneti-
cally engineered cells, instead of HCG, has been described
as a possible preventive measure for OHSS and an effec-
tive alternative to HCG. The pharmacokinetics and bio-
activity of rLH appear to be similar to those of native
LH, possibly making it less likely than HCG to cause
OHSS. However, only 13% physicians advocated the ad-
ministration of rLH instead of HCG. This low percentage
is probably due to the fact that in many countries rLH is
not commercialized, as was commented by several re-
spondents.47 The risk for OHSS may be also reduced by
using subcutaneous or nasal administration of GnRh-a
that is acceptable as an effective alternative in place of
HCG to induce preovulatory LH surge, which unfortun-
atelly could be used only in the cycle where down regu-
lation has not been affected with GnRh-a. The relatively
short life – life 3 to 5 hours of GnRh-a may conceivably
eliminate the risk of OHSS in non-conception cycles.
The main disadvantage in this regimen is that it is not
applicable with GnRh-a suppression, which are the most
prevalent treatment schedules currently used. Alterna-
tivelly, in patients who have been pre-treated with GnRh
antagonists during ovarian stimulation, the pituitary go-
nadotrophins retain their sensitivity to GnRh-a to induce
ovulation, enabling the resulting endogenous LH surge,
which is probably less likely to be associated with OHSS
than the use of HCG.21–23,25,43,48
It has been suggested that follicullar aspiration after
HCG triggering, but before oocyte retrieval, protects
against severe OHSS by causing intrafollicular hemor-
rhage, leading to a decline in the ovarian production of
substances responsible for its occurrence in high risk pa-
tients of OHSS.49 Few physicians (9%) chose to proceed
to two follicular aspirations during the same IVF cycle,
a method which has been previously published. By using
early follicular aspiration more oocytes were retrieved,
however the method of follicular aspiration followed by
oocyte retrieval was not selected by all physicians be-
cause it was considered to be to invasive.1,25,49,50
Cryopreservation avoids the risk of pregnancy and of
endogenous production of HCG, a well-known promot-
ing factor of severe OHSS. Withholding of embryo trans-
fer and its replacement at a later date as an elective cry-
opreservation of all embryos, a decline in the severity of
OHSS has been found, but without totally eliminating it.
By using cryopreservation the reduction of the risk of
OHSS was estimated to be similar to that obtained by
coasting and that of albumin administration. It is possi-
ble that cryopreservation was less often selected because
of its negative psychological impact and the prevailing
opinion that the chances for pregnancy are reduced when
thawed embryos rather than fresh ones are transferred.
However, very favorable implantation rates in a series
of cases with cryopreserved embryos for OHSS preven-
tion were obtained, although one should note that cryop-
reservation is not available in all countries.47,51,52 Alter-
natively, instead of cryopreservation a novel approach
of prolonging the evaluation time for up to 5 and 6 days
after the oocyte retrieval and transferring of a single zona
free embryo (blastocyste) offers for patients at risk for
developing OHSS.53
It is consistently well-known that HCG could exacer-
bate OHSS and there is a significantly higher incidence
of the syndrome if ovulation was triggered with HCG.
Severe OHSS is very rare in the absence of luteal sup-
port with HCG, either exogenous or pregnancy-derived.
Therefore, if luteal HCG is withheld and luteal support
bypassed and substituted with progesterone, OHSS will
be largely prevented. It is not clear whether HCG or pro-
gesterone provides the better pregnancy rates, and meta-
analysis of all IVF luteal support regimens found no sig-
nificant difference between the two options. In contrast,
when cycles using GnRh-a were analyzed separately, luteal
support with HCG was associated with a significantly
higher pregnancy rate. Given the likelihood that luteal
HCG can induce or worsen OHSS, it would therefore
seem prudent to avoid its use in cycles deemed to be at
risk for this complication.1,25,54
The existence of several substances with inhibiting
effects on VEGF offers a new modality of preventing
vascular permeability in patients with OHSS.33,55 Admin-
istration of corticosteroids (methylprednisolone) used by
some failed to demonstrate any beneficial effect on pre-
venting OHSS.56 Conversely, the others demonstrated that
corticosteroids appear to reduce the risk for OHSS thus
helping to avoid hospitalization, reducing cycle cancel-
lations, and improving the cost-effectiveness of IVF cy-
cles.57 Metformin appears to reduce the risk for OHSS
during gonadotrophin stimulation in women with PCOS
by lowering intraovarian androgen levels and E2 blood
concentrations.58 Although pentoxyphyline was found to
inhibit TNF-alpha synthesis, it did not prevent ascites for-
mation, despite the observation in decrease in ovarian
weight and number of ovulations in OHSS.59
In the cycle of ovulation induction where OHSS seems
likely, conversion to IVF and aspiration of all the follicles
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has been advised, however later persisted a 15% inci-
dence of severe OHSS.1,3,25,26
Treatment
The treatment of OHSS is conservative and bed rest
with symptomatic relief are usually sufficient for mild
and moderate stages. In mild cases, symptoms subside
usually within a few days, while in moderate cases, symp-
toms can require up to three weeks to subside especially
when pregnancy occurs. Severe OHSS can be life-threat-
ening and patients therefore should be hospitalized and
monitored closely. Patients are put on bed rest, daily body
weight and fluid balance monitoring are necessary; he-
matocrit, coagulation, and kidney functions, serum elec-
trolyte and albumin studies are obtained daily, as well as
ultrasound scan of the pelvis and chest; oxygen satura-
tion measurements (using an oxymeter while breathing
air, and if less than 85% using blood gases) should be
performed if dyspnea is notified; and pelvic examination
should be avoided because of fragility of the enlarged
ovaries, and ovarian surgery is relatively contraindicat-
ed.1,3,15,16,25
Hypovolemia and hemoconcentration need immedi-
ate corrections. When necessary, intravenous crystaloid
infusion or macromolecular plasma expanders (human
albumin or hydroxyethyl) administered around the time
of oocyte retrieval were first suggested as measures in
the prevention and treatment of severe OHSS in high
risk women to maintain central venous pressure. Albu-
min was generally considered as a safe product that acts
by inactivating and binding the ovarian vasoactive fac-
tors which contribute to the development of OHSS, with
a half-life up to 19 days. The role of albumin is also to
maintain plasma oncotic pressure by drawing fluid from
the third space into the vascular compartment, and pre-
venting the ensuing effects of hypovolemia, ascites, and
hemoconcentration, representing the volume expander
of choice.3,24,25,43,51,59,60 However, more recent, prospec-
tive, randomized, placebo-controlled double blind stud-
ies were controversial because they could not confirm
this beneficial effect. Paradoxycally, it was concluded
that albumin is ineffective and even dangerous because
of well-documented serious risks, which include exac-
erbation of the syndrome, and therefore this form of treat-
ment should not be included in the regimen of OHSS
prevention and treatment.3,61–64
Diuretics, although highly controversial, do have a role
in the treatment of OHSS, and should be administered
with caution since the fluids in the abdominal and tho-
racic cavity are not responsive, and even the further in-
travascular depletion can cause hypotension, shock and
thrombosis. Therefore, diuretics should be administered
following pre-treatment with albumin when hemodilu-
tion has been achieved.1,3,7,16,23
Paracentesis constitutes the single most important treat-
ment modality in life-threatening OHSS not controlled
by medical therapy. It is usually immediatelly accompa-
nied with dramatic improvement in clinical symptoms
and almost instantaneous diuresis. The indications for
paracentesis include the need for symptomatic relief, a
tense ascites, oliguria, rising creatine and creatinine clear-
ance, and hemoconcentration unresponsive to medical
therapy. Ultrasound transvaginal guidance is obligatory,
and up to 4 litres of ascitic fluid may be removed by
slow drainage.1,3,23 The best correlation with the severity
of OHSS is an elevated hematocrit, which directly reflects
an intravascular volume depletion and blood viscosity.
In cases of impeding thromboembolic phenomena he-
parin is indicated, whereas cauterization or laser vapori-
zation, abdominal surgery and therapeutic termination
of pregnancy are reserved in a life-threatening situations
when all other measures have failed.1,3,63–65
Despite many years of clinical experience, pathophys-
iology is still poorly understood and there is no reliable
test to predict who of the patients at risk will subsequently
develop OHSS. Additional and properly conducted stud-
ies with larger number of patients are required in order
to determine the best method and strategy for the preven-
tion and treatment of OHSS.
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